COmparison of Xience PrimE Versus REsolute Integrity in Diabetes or Small Vessel Disease

Inclusion Criteria: 1. Age \> 18 years 2. Patients requiring stent procedure (visual diameter stenosis ≥ 50%) 3. Stable angina with evidence of myocardial ischemia, acute coronary syndrome(ST segment elevation, non-ST segment elevation acute myocardial infarction, and unstable angina) 4. Patients diagnosed of type 2 diabetes or small vessel disease 5. Patients willing to participate in the study through written consent Exclusion Criteria: 1. Those hypersensitive to or abstaining from heparin, aspirin, clopidogrel, contrast medium, zotarolimus, or everolimus. 2. Pregnant women or those having future plans for pregnancy. 3. Those having hemorrhagic disease or blood-clotting disorders (including heparin-induced thrombocytopenia), or those rejecting blood transfusion. 4. Those having medical history of digestive and urinary system bleeding during the last 3 months, or who have received major surgery within 2 months. 5. Those with thrombocytopenia (\< 100,000/mm3) or hemoglobin 10.0 g/dL or less. 6. Those planning a surgery that requires the discontinuation of antiplatelet drugs within next 12 months (especially, thienopyridines type). 7. When the remaining survival period is expected to be less than 1 year. 8. Restenosis lesion 9. Left main coronary artery lesion 10. Saphenous vein graft stenosis lesion 11. Left ventricular ejection fraction \< 30% 12. Cardiac shock 13. Those with liver function failure: When liver enzyme level (ALT) is 3 times the normal upper limit. 14. Type I diabetes